Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncogenic Transcription and RNA Splicing Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NONO drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NONO Recombinant Protein (Full-Length & Truncated domains) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. Suitable for biochemical binding assays. |
View NONO Products |
| Gene Delivery | NONO Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View NONO Products |
| Benchmark Ab | Anti-NONO Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP assays. |
View NONO Products |
| Validator | NONO siRNA Set For knockdown verification and functional phenotypic assays. |
View NONO Products |
| Related Target A | SFPQ Essential heterodimerization partner of NONO in paraspeckle formation and transcriptional regulation. |
View SFPQ Products |
| Related Target B | TFE3 Fusion partner in NONO-TFE3 renal cell carcinoma; critical for downstream oncogenic signaling. |
View TFE3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimerization & Complex Stability | Highly stable recombinant NONO and SFPQ proteins available for heterodimerization binding assays. |
| Selectivity Screening (DBHS Family) | Homolog panel proteins (NONO, SFPQ, PSPC1) strictly verified by mass spectrometry to exclude cross-reactivity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-affinity positive controls included. |
| False Positives in Knockdown | Multi-sequence validated siRNA pool included for target-specific knockdown verification. |
Live NONO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NONO therapeutics is intensifying, with major players shifting focus from traditional gene silencing to small-molecule inhibitors of protein-protein interactions (PPI) and targeted protein degradation (PROTACs). As first-generation therapies targeting RNA-binding proteins reach the clinic, the next wave of R&D is targeting the disruption of DBHS family heterodimerization and the NONO-TFE3 fusion oncogene in refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Prostate Cancer, Melanoma | High-purity recombinant NONO/SFPQ proteins for FP and TR-FRET assays. |
| PROTAC (Degrader) | Targeted Protein Degradation Pioneers | Breast Cancer, Glioblastoma | Lentivirus-mediated stable cell lines expressing tagged-NONO for degradation kinetics. |
| Antisense Oligonucleotides (ASO) | RNA-targeting Biopharma | Rare Diseases, Genitourinary Cancers | Validated siRNA sets and high-specificity antibodies for target knockdown confirmation. |